10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
10x Genomics (TXG) reported a Q4 loss of $0.40 per share, which was larger than the Zacks Consensus Estimate of a $0.32 loss. However, the company topped revenue estimates.

February 13, 2025 | 12:00 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
10x Genomics reported a Q4 loss of $0.40 per share, missing the Zacks Consensus Estimate of $0.32. Despite the larger loss, the company exceeded revenue expectations.
The larger-than-expected loss per share could negatively impact investor sentiment. However, the fact that revenue exceeded expectations may offset some of the negative impact, leading to a neutral short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100